Get the Stockscreener App
33.01
5.42%
-1.89
After Hours:
33.64
0.63
+1.91%
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
Leerink Partnrs Has Optimistic Outlook of BBIO Q1 Earnings - MarketBeat
Y Intercept Hong Kong Ltd Increases Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
What is Leerink Partnrs' Forecast for BBIO Q3 Earnings? - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownTime to Sell? - MarketBeat
Q1 Earnings Estimate for BBIO Issued By Leerink Partnrs - MarketBeat
Brian C. Stephenson Sells 8,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares - MarketBeat
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Insights
BridgeBio Pharma Strengthens Financial Position with Note Issuance - TipRanks
BridgeBio Pharma Issues $575 Million Of 1.75% Convertible Senior Notes Due 2031 - Marketscreener.com
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs - MedCity News
BridgeBio Pharma, NetApp, Talen Energy - TradingView
Raymond James resumes coverage on BridgeBio with 'outperform' on heart drug optimism - TradingView
BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive
BridgeBio Pharma's cancer-focused spinout plans $450 million deal to go public - The Business Journals
BridgeBio spinout to go public in SPAC deal (HLXB:NASDAQ) - Seeking Alpha
Helix Acquisition to Merge With BridgeBio Oncology Therapeutics -February 28, 2025 at 09:37 am EST - Marketscreener.com
$450M Deal Powers New Cancer-Fighting Biotech: What's Inside BridgeBio's Oncology SPAC Merger? - StockTitan
BridgeBio price target raised to $46 from $45 at BofA - TipRanks
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsBBIO - ACCESS Newswire
BridgeBio prices offering of $500 million convertible senior notes due 2031 - MSN
BridgeBio Pharma CFO Brian Stephenson sells $282,114 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma CEO Neil Kumar sells $2.52 million in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Bayer Execs Roth And Eckhardt On Current And Future Pharma Growth - Insights
BridgeBio Pharma CFO Brian Stephenson sells $282,114 in stock - Investing.com India
BridgeBio Pharma CEO Neil Kumar sells $2.52 million in stock - Investing.com India
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
BridgeBio Pharma (NASDAQ:BBIO) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Principal Financial Group Inc. Reduces Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
HealthInvest Partners AB Buys 49,600 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Latham & Watkins Advises on BridgeBio’s US$500 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey
BridgeBio up after $500 mln convertible debt deal priced - TradingView
BridgeBio Pharma Prices $500 Million Convertible Senior Notes Offering -February 26, 2025 at 05:59 am EST - Marketscreener.com
BridgeBio Pharma, Inc. Prices $500 Million Convertible Senior Notes Offering to Lower Debt and Enhance Financial Flexibility - Nasdaq
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt - GlobeNewswire
How BridgeBio's $500M Debt Refinancing Could Strengthen Its Financial Future - StockTitan
When the Price of (BBIO) Talks, People Listen - Stock Traders Daily
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $52.00 at Scotiabank - MarketBeat
BridgeBio announces offering of convertible senior notes to refinance debt - MSN
BridgeBio's SWOT analysis: genetic disease stock poised for growth - Investing.com India
BridgeBio’s SWOT analysis: genetic disease stock poised for growth - Investing.com
Insider Sell-Offs Shake BridgeBio Pharma Stocks - TipRanks
BridgeBio Pharma (NASDAQ:BBIO) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
BridgeBio announces $500 million convertible notes offering By Investing.com - Investing.com Nigeria
BridgeBio Pharma To Offer $500 Million Convertible Senior Notes Due 2031 - TradingView
BridgeBio announces $500 million convertible notes offering - Investing.com India
BridgeBio stock falls on convertible notes offering By Investing.com - Investing.com South Africa
BridgeBio stock falls on convertible notes offering - Investing.com India
BridgeBio Pharma Announces $500 Million Convertible Senior Notes Offering to Strengthen Balance Sheet and Enhance Financial Flexibility - Nasdaq
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt - WICZ
BridgeBio Initiates Long Term Debt Management Strategy and - GlobeNewswire
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of - The Bakersfield Californian
Can BridgeBio's $500M Debt Makeover Transform Its Financial Future? - StockTitan
Peninsula drugmaker nails heart failure drug launch in battle with Big PharmaSan Francisco Business Times - The Business Journals
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):